Detalles de la búsqueda
1.
Antiretrovirals and Weight Change: Weighing the Evidence.
Clin Infect Dis
; 2024 Apr 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38606799
2.
Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment.
AIDS Care
; 28(3): 401-8, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26489045
3.
A pseudo-response approach to constructing confidence intervals for the subset of patients expected to benefit from a new treatment.
J R Stat Soc Ser C Appl Stat
; 73(2): 522-539, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38746649
4.
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.
Lancet
; 379(9835): 2439-2448, 2012 Jun 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-22748591
5.
Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
HIV Clin Trials
; 14(5): 216-23, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-24144898
6.
Corrigendum: Translating the observed differences in interleukin-6 levels between some antiretroviral regimens into potential long-term risk of serious non-AIDS events: A modeling study.
Front Immunol
; 14: 1148980, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36875086
7.
Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
Lancet
; 378(9787): 229-37, 2011 Jul 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-21763935
8.
Impact of Tai Chi exercise on multiple fracture-related risk factors in post-menopausal osteopenic women: a pilot pragmatic, randomized trial.
BMC Complement Altern Med
; 12: 7, 2012 Jan 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-22289280
9.
Translating the observed differences in interleukin-6 levels between some antiretroviral regimens into potential long-term risk of serious non-AIDS events: A modeling study.
Front Immunol
; 13: 976564, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36426353
10.
Similar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patients.
HIV Clin Trials
; 12(3): 131-40, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-21684853
11.
Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.
Value Health
; 14(5): 657-64, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-21839403
12.
Similar virologic and immunologic efficacy with fosamprenavir boosted with 100 mg or 200 mg of ritonavir in HIV-infected patients: results of the LESS trial.
HIV Clin Trials
; 11(5): 239-47, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-21126954
13.
Tai Chi for osteopenic women: design and rationale of a pragmatic randomized controlled trial.
BMC Musculoskelet Disord
; 11: 40, 2010 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-20193083
14.
Low-level viremia in HIV-1 infection: consequences and implications for switching to a new regimen.
HIV Clin Trials
; 10(2): 116-24, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-19487182
15.
Prescribing and using self-injectable antiretrovirals: how concordant are physician and patient perspectives?
AIDS Res Ther
; 6: 2, 2009 Feb 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-19196474
16.
Virologic response to lopinavir-ritonavir-based antiretroviral regimens in a multicenter international clinical cohort: comparison of genotypic interpretation scores.
Antimicrob Agents Chemother
; 52(11): 4050-6, 2008 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-18710915
17.
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.
Lancet
; 369(9568): 1169-78, 2007 Apr 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-17416261
18.
Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily.
HIV Clin Trials
; 9(4): 213-24, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18753116
19.
Short-term safety and tolerability of a once-daily fixed-dose abacavir-lamivudine combination versus twice-daily dosing of abacavir and lamivudine as separate components: findings from the ALOHA study.
Pharmacotherapy
; 28(3): 314-22, 2008 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-18294111
20.
Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis.
AIDS
; 21(6): F1-10, 2007 Mar 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-17413684